JBM (Healthcare) (HKSE:02161) Research & Development: HK$0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02161 JBM (Healthcare) Ltd HKSE:02161
86 GF Score
Price HK$1.94
GF Value HK$2.08
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is JBM (Healthcare) Research & Development?

JBM (Healthcare) HKSE:02161 86 Research & Development is HK$0.0 Mil as of Mar. 2026. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.08 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. JBM (Healthcare)'s Research & Development for the six months ended in Mar. 2026 was HK$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.0 Mil.

JBM (Healthcare)  (HKSE:02161) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

JBM (Healthcare) Research & Development Related Terms

JBM (Healthcare) Research & Development Historical Data

* Premium members only.

The historical data trend for JBM (Healthcare)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JBM (Healthcare) Research & Development Chart

JBM (Healthcare) Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

JBM (Healthcare) Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02161
86GF Score
JBM (Healthcare) Ltd HKSE:02161
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JBM (Healthcare) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.0 Mil mean?
JBM (Healthcare) (HKSE:02161) has a Research & Development of HK$0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on JBM (Healthcare) and its competitors.
Is JBM (Healthcare)'s Research & Development too high?
JBM (Healthcare)'s current Research & Development is HK$0.0 Mil. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Research & Development compare to ZTS?
JBM (Healthcare)'s Research & Development of HK$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on JBM (Healthcare) and its competitors. JBM (Healthcare)'s current Research & Development is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.94 — trading 6.7% below its estimated fair value. The current Research & Development is HK$0.0 Mil. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Research & Development is HK$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?

Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued. The current stock price of HK$1.94 is trading 6.7% below its estimated GF Value™ of HK$2.08. GuruFocus considers JBM (Healthcare) to be Fairly Valued.

Key valuation signals for HKSE:02161:

  • Research & Development: HK$0.0 Mil
  • GF Value™: HK$2.08 vs. price of HK$1.94 (6.7% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JBM (Healthcare) Business Description

Address 108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score

Get the complete analysis for HKSE:02161

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.94
Price
HK$2.08
GF Value